Department of Health and Human Services
Public Health Service
4040 N. Central Expwy
July 19, 2006
VIA FEDERAL EXPRESS
301 W Witt
Wolfe City, TX 75496
Ref. No. 2006-DAL-WL-26
Dear Mr Ovard:
This letter concerns your firm’s marketing of the product 35% Food Grade Hydrogen Peroxide on your website, www.dfwx.com/h2o2.htm. According to information on your website, 35% Food Grade Hydrogen Peroxide is intended to prevent, treat, or cure disease conditions or to affect the structure or function of the body. Statements on your website that document these intended uses include, but are not limited to, the following:
- 35% Food Grade Hydrogen Peroxide
- “Thus, it is believed that hydrogen peroxide may help prevent and even combat cancer.”
- “Conditions which can be treated with H202 [hydrogen peroxide] include those conditions which can be treated with antibiotics, but without the serious toxicity often associated with laboratory produced synthetic antibiotics. Some of these conditions are candidiasis (yeast), viral infections, influenza, the common cold, sinus infection, Epstein-Barr virus and gangrene.”
- “Hydrogen peroxide also has been found to dissolve cholesterol and calcium deposits associated with atherosclerosis. Therefore, it is a good treatment for vascular disorders. This can result in lessening or disappearance of angina … can help reverse some of the damage left over by a stroke.…”
- “Some doctors believe AIDS and cancer can be helped with hydrogen peroxide.”
- “It also clears the lungs, in cases of emphysema.…”
- “In addition, hydrogen peroxide benefits asthma, leukemia, multiple sclerosis, degenerative spinal disc disease and high blood pressure. It is particularly effective with asthma, arthritis and back disorders.”
35% Food Grade Hydrogen Peroxide is a drug, as defined by Section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 USC 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or other animals. Moreover, this product is a new drug, as defined by Section 201(p) of the Act, 21 USC 321(p), because it is not generally recognized as safe and effective for its labeled uses. Under Sections 301(d) and 505(a) of the Act, 21 USC 331(d) and 355(a), a new drug may not be introduced or delivered for introduction into interstate commerce unless an FDA approved application is in effect for it. Your sale of 35% Food Grade Hydrogen Peroxide without an approved application violates these provisions of the Act.
Furthermore, because this product is offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners, adequate directions cannot be written so that a layman can use this product safely for its intended uses. Thus, 35% Food Grade Hydrogen Peroxide’s labeling fails to bear adequate directions for its intended uses, causing it to be misbranded under Section 502(f)(1) of the Act, 21 USC 352(f)(1).
You also make false and misleading promotional statements on your website regarding this product. For example, your website states, “Because it is produced in the human body, it is undeniably safe.” Even if this substance is present in the body, this in no way makes the use of an exogenous product, at the strength and for the indications associated with your product, safe. Thus, your product is misbranded under Section 502(a) of the Act, 21 USC 352(a).
The above violations are not intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure that the drug products that you manufacture or distribute meet all of the requirements of the Act and its implementing regulations. Federal agencies are advised of the issuance of all warning letters about drugs and devices so that they may take this information into account when considering the award of contracts.
You must immediately correct these violations. If you do not immediately correct them, you may be subject to enforcement action against you without further notice. The Act provides for the seizure of illegal products and for an injunction against the manufacturer and distributors of illegal products. Individuals and businesses that violate the Act may also be subject to criminal prosecution.
You must notify this office in writing within 15 working days of receipt of this letter as to the steps that you have taken to correct the above-listed violations and to assure that similar violations will not recur. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be made. Additionally, if your firm does not manufacture the product identified above, your reply should include the name and address of the manufacturer. If the firm from which you receive the product is not the manufacturer, please include the name of your supplier in addition to the manufacturer
Address your reply to the US Food and Drug Administration, 4040 N Central Expwy #300, Dallas, TX 75204, Attn: Sherrie L. Krolczyk, Compliance Officer.
A description of the new drug approval process can be found on FDA’s internet website at www.fda.gov/cder/regulatory/applications/default.htm. Any questions you may have regarding this process should be directed to the Food and Drug Administration, Division of Drug Information (HFD-240), Center for Drug Evaluation and Research, 5600 Fishers Ln, Rockville, MD 20857.
Michael A. Chappell
This page was posted on February 12, 2008.